Gilles R. Dagenais

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 3K citations · Full text

Medicine, Endocrinology, Pharmacology +14

Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease

John W. Eikelboom, Stuart J. Connolly, Jackie Bosch et al. · New England Journal of Medicine · 2017 · 2.4K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study

Salim Yusuf, Philip Joseph, Sumathy Rangarajan et al. · The Lancet · 2019 · 2K citations · Full text

Public Health, Chronic Disease Prevention, Preventive Medicine +17

World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions

Stephen Kaptoge, Lisa Pennells, Dirk De Bacquer et al. · The Lancet Global Health · 2019 · 1.2K citations · Full text

Medicine, Cardiology, Preventive Medicine +17

Association of Cardiometabolic Multimorbidity With Mortality

Emanuele Di Angelantonio, Stephen Kaptoge, David Wormser et al. · JAMA · 2015 · 1.1K citations · Full text

Public Health, Chronic Disease Prevention, Clinical Epidemiology +10